PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases
Airway mucus hypersecretion (AMH) is a key pathophysiological feature of chronic airway inflammatory diseases such as bronchial asthma, cystic fibrosis, and chronic obstructive pulmonary disease. AMH contributes to the pathogenesis of chronic airway inflammatory diseases, and it is associated with r...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2012/256874 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550671190065152 |
|---|---|
| author | Yongchun Shen Lei Chen Tao Wang Fuqiang Wen |
| author_facet | Yongchun Shen Lei Chen Tao Wang Fuqiang Wen |
| author_sort | Yongchun Shen |
| collection | DOAJ |
| description | Airway mucus hypersecretion (AMH) is a key pathophysiological feature of chronic airway inflammatory diseases such as bronchial asthma, cystic fibrosis, and chronic obstructive pulmonary disease. AMH contributes to the pathogenesis of chronic airway inflammatory diseases, and it is associated with reduced lung function and high rates of hospitalization and mortality. It has been suggested that AMH should be a target in the treatment of chronic airway inflammatory diseases. Recent evidence suggests that a key regulator of airway inflammation, hyperresponsiveness, and remodeling is peroxisome proliferator-activated receptor gamma (PPARγ), a ligand-activated transcription factor that regulates adipocyte differentiation and lipid metabolism. PPARγ is expressed in structural, immune, and inflammatory cells in the lung. PPARγ is involved in mucin production, and PPARγ agonists can inhibit mucin synthesis both in vitro and in vivo. These findings suggest that PPARγ is a novel target in the treatment of AMH and that further work on this transcription factor may lead to new therapies for chronic airway inflammatory diseases. |
| format | Article |
| id | doaj-art-059c455b67d848fea04375bfdfe432b5 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-059c455b67d848fea04375bfdfe432b52025-02-03T06:06:01ZengWileyPPAR Research1687-47571687-47652012-01-01201210.1155/2012/256874256874PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory DiseasesYongchun Shen0Lei Chen1Tao Wang2Fuqiang Wen3Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, ChinaDivision of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, ChinaDivision of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, ChinaDivision of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, ChinaAirway mucus hypersecretion (AMH) is a key pathophysiological feature of chronic airway inflammatory diseases such as bronchial asthma, cystic fibrosis, and chronic obstructive pulmonary disease. AMH contributes to the pathogenesis of chronic airway inflammatory diseases, and it is associated with reduced lung function and high rates of hospitalization and mortality. It has been suggested that AMH should be a target in the treatment of chronic airway inflammatory diseases. Recent evidence suggests that a key regulator of airway inflammation, hyperresponsiveness, and remodeling is peroxisome proliferator-activated receptor gamma (PPARγ), a ligand-activated transcription factor that regulates adipocyte differentiation and lipid metabolism. PPARγ is expressed in structural, immune, and inflammatory cells in the lung. PPARγ is involved in mucin production, and PPARγ agonists can inhibit mucin synthesis both in vitro and in vivo. These findings suggest that PPARγ is a novel target in the treatment of AMH and that further work on this transcription factor may lead to new therapies for chronic airway inflammatory diseases.http://dx.doi.org/10.1155/2012/256874 |
| spellingShingle | Yongchun Shen Lei Chen Tao Wang Fuqiang Wen PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases PPAR Research |
| title | PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases |
| title_full | PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases |
| title_fullStr | PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases |
| title_full_unstemmed | PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases |
| title_short | PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases |
| title_sort | pparγ as a potential target to treat airway mucus hypersecretion in chronic airway inflammatory diseases |
| url | http://dx.doi.org/10.1155/2012/256874 |
| work_keys_str_mv | AT yongchunshen ppargasapotentialtargettotreatairwaymucushypersecretioninchronicairwayinflammatorydiseases AT leichen ppargasapotentialtargettotreatairwaymucushypersecretioninchronicairwayinflammatorydiseases AT taowang ppargasapotentialtargettotreatairwaymucushypersecretioninchronicairwayinflammatorydiseases AT fuqiangwen ppargasapotentialtargettotreatairwaymucushypersecretioninchronicairwayinflammatorydiseases |